Summary
Bridge rounds are meant to carry a company to its next priced round. Trouble starts when nobody can yet say when that round will happen or who will lead it. This paper draws on a mandate for a North American industrial biotechnology company with a biological crop-protection platform: more than a decade old, backed by grants and paying development partners, and seeking a bridge ahead of a Series A that had no confirmed date, size or lead investor.
In my view you can't price a bridge off a round nobody has defined yet. It needs its own terms: a fixed amount with a realistic first close, a valuation cap, a maturity with a fallback, clear ranking against existing debt, and proceeds tied to milestones an investor can put a date on. With those in place the bridge can be judged on its own merits. Without them, most specialist investors will just wait for the Series A.
1. The market: selective, and with a long memory
Source: AgFunder Global AgriFoodTech Investment Report 2026.
There's still capital for agricultural biotechnology, but investors have become pickier. They're backing companies with tangible science, real unit economics and a clear path to revenue, and they are writing fewer cheques.
Most investors in RNA-based crop protection also know the GreenLight Biosciences story. The company listed through a SPAC in early 2022 at an enterprise value of about $1.2bn, and in May 2023 agreed to be taken private by a consortium led by Fall Line at roughly $45.5m. Later that year it won the first US EPA registration of a sprayable RNA insecticide, Calantha, for Colorado potato beetle, after more than four years of review. By 2025 it had closed a Series C that included $25m from Just Climate and signed up to €35m of venture debt with the European Investment Bank.
For investors the takeaway is about time. Approvals take years, regulators set the pace, and the balance sheet has to last until then. Any company raising in this space will be asked how its financing avoids the same trap.
2. The situation
The company had many of the things investors look for: more than ten years of operating history, patents in several jurisdictions, field data, grant funding, and global corporates paying to co-develop products. It wanted a bridge to reach a Series A.
But the documents it had prepared did not agree with each other. Different versions gave different amounts, different instruments and different Series A dates. Headcount and patent counts varied between sources. None of this suggested bad faith; it is common in companies that have raised in small steps over many years. It did mean that no investor could have priced the bridge as presented.
So the first job was to get to one set of numbers, each tied to a source document, before any investor saw anything.
3. Why a discount-only note does not work here
The simplest bridge is a convertible note or SAFE that converts into the next round at a discount. It works when the next round is close and well defined. When it isn't, you run into three problems.
- No ceiling. Without a valuation cap, a strong Series A leaves the bridge investor with only the discount, even though they took the earlier and larger risk.
- No end date. Without a maturity and a default conversion price, the investor has no answer to the question of what happens if the Series A never comes.
- No ranking. If the company already has convertible debt or short-term loans, the new money needs to know where it sits and whether it is being used to repay them.
The cap is the term that matters most. The table below uses round, made-up numbers (not the client's terms) for a note with a 20% discount, with and without a $50m cap.
| Series A pre-money | Note converts at (discount only) | Note converts at (with $50m cap) |
| $40m | $32m | $32m |
| $80m | $64m | $50m |
| $120m | $96m | $50m |
Illustrative only. Conversion price shown as the effective pre-money valuation at which the note converts.
The cap changes nothing if the Series A is modest, and protects the bridge investor if it is strong. Which is why founders tend to resist it and experienced investors tend to insist on it. If a company really expects a strong Series A, offering a cap shouldn't worry it.
4. Size the bridge to milestones, not to a range
A bridge described only as a wide range, where the top is several times the bottom, tells an investor the company has not decided what the money is for. It's better to list the milestones that will move the Series A valuation, put a date and a cost against each, and size the bridge to reach them with a cash buffer.
For a biological crop-protection company those milestones are usually regulatory-grade field data, a signed commercial or manufacturing partnership, first licence or royalty revenue, and a named Series A lead. A realistic first close is often the amount two to four specialist investors will commit together. A much larger bridge normally needs an anchor, such as a strategic partner or a public co-investor, before anyone else will follow.
5. What the money repays matters
Investors read the use of proceeds closely. New money that funds trials, patents and hiring buys future value. New money that repays short-term debt, especially alongside asset sales, reads as a company funding its past. Both can be legitimate, but they need to be separated and explained. If part of the bridge refinances existing debt, say so plainly, show the lender and maturity, and show that the rest of the round still reaches the milestones.
6. Lead with one product
Platform companies often present every application at once: crop protection, food, cosmetics, animal health, materials. To a bridge investor this raises the question of what the company actually is. It usually works better to lead with the one programme closest to revenue and regulatory approval, and treat the others as partner-funded options that add value without consuming the bridge.
7. Who funds a bridge like this
- Specialist investors first. Agricultural, food and industrial biotechnology funds, and the corporate venture arms of crop protection, ingredient and fermentation groups, who already understand biological timelines.
- Long-horizon private capital. Family offices with agriculture or life-science holdings, and food-security focused capital, including in the Gulf.
- Blended and public capital. Impact funds with a pesticide-reduction thesis, venture debt providers, and public development lenders. The European Investment Bank's venture debt for GreenLight shows public capital will back RNA biologicals once regulatory progress is visible.
The list should be short and specialist. In a sector with a known cautionary tale, a broad generalist process tends to use up credibility before it finds money.
8. Bridge term checklist
- One amount, with a minimum first close and the runway it buys
- One instrument, SAFE or convertible note, with its reasons
- A valuation cap, plus the conversion discount
- Interest or PIK terms, if a note
- A maturity date and a default conversion price if no Series A arrives
- Ranking against existing convertibles and short-term debt
- Use of proceeds, split between new milestones and refinancing
- Dated milestones the bridge will reach before the Series A
- A reconciled data room: accounts, cap table, patents, trial reports
- Written permission for any third-party research shown to investors
9. What this mandate is teaching me
I've come to see a bridge as its own investment with its own risk, rather than an early slice of the Series A, and it needs pricing that way. The companies that raise bridges well stop talking about the round they hope to do next and pin down the one in front of them: how much, on what terms, for which milestones, and what happens if the next round is late. Investors in this sector remember the last company that ran out of time, so that kind of discipline goes a long way.
Sources
- AgFunder, Global AgriFoodTech Investment Report 2026
- AgFunderNews, "Agrifoodtech funding is flat but the story is shifting"
- Fierce Biotech, GreenLight returns to private market in $46M deal (May 2023)
- GreenLight Biosciences, EPA registration of Calantha
- Just Climate, GreenLight Series C (March 2025)
- European Investment Bank, €35 million for GreenLight Biosciences (2025)
This paper is for discussion only and is not investment advice. It draws on a live mandate; the company is not named and no client terms are disclosed. The conversion table uses hypothetical numbers.